Navigation Links
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
Date:12/1/2008

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is currently enrolling patients in a Phase Ib study evaluating ANA598 for the treatment of patients chronically infected with HCV.

Under the FDA Modernization Act of 1997, fast track designation is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions. Compounds selected must demonstrate the potential to address an unmet medical need for such a condition. Mechanisms intended to facilitate development include opportunities for frequent dialogue with FDA reviewers and for timely review of submitted protocols. However, the designation does not guarantee approval or expedited approval of any application for the product. The granting of fast track status for the ANA598 development program is consistent with the need for HCV treatments with novel mechanisms of action, oral administration, non-overlapping resistance profiles and improved safety and efficacy over the existing standard of care for both treatment-naive and treatment-experienced patients.

"The FDA's fast track designation for ANA598 acknowledges the need for new HCV therapies to improve treatment outcomes," commented James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We anticipate continuing to work closely with the FDA on the development and regulatory review of ANA598, one of the few non-nucleoside polymerase inhibitors in clinical development for the treatment of HCV. We continue to
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been ... comes with a second treatment cup to help prevent and ... cup is thinner on the edges for a softer contact ... and uneven surfaces on the face, neck and décolleté. Choose ... on areas such as the cheeks and neck, or opt ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2
... Jan. 20, 2011 MedImmune,s Oncology group announced today ... broadly suppresses pathways that have been shown to play ... many solid tumors. The study, published in the February ... of the American Association for Cancer Research), suggests that ...
... Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, ... company that creates, develops and tests innovative HIV/AIDS vaccines, is ... Community Awards.  Dr. Robinson will be honored at the GaBio ... Atlanta,s Fox Theater. Dr. Robinson is the developer ...
... 2011 Reportlinker.com announces that a new market ... Hospital General Radiology Census ... is the most comprehensive European market report on ... IT systems (PACS) in European hospitals. Hospitals are ...
Cached Biology Technology:Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells 2Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells 3GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony 2GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony 3Reportlinker Adds Hospital General Radiology Census 2
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... software and services, previously announced on June 26, 2014 ... cash dividend of $1.75 per share, or approximately $40 ... of July 10, 2014 and a payment date of ... NASDAQ that it had set an ex-dividend date for ...
(Date:7/10/2014)... 2014 According to the new ... And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), ... Banking & Finance), and Geography - Global Trends & ... global Fingerprint Sensors Market is projected to cross $14.35 ... 16.8% from 2014 to 2020. Browse more ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... St. Jude Children,s Research Hospital have reported details of ... enzyme essential for the influenza virus, replication. Since all ... researchers believe their findings will yield drugs that can ... be resistant to current antiviral treatments. When new ...
... State University suggest that a "fight" between bacteria normally living ... another type of bacteria, may be linked to two types ... continues after the instigator bacteria have been cleared by the ... GSU Center for Inflammation, Immunity and Infection. That fight can ...
... UCLA stem cell researchers have found for the first ... endothelium, the place where blood stem cells are made ... lack of one transcription factor, a type of gene ... the precursors that normally generate blood stem and progenitor ...
Cached Biology News:Target for potent first-strike influenza drugs identified 2Target for potent first-strike influenza drugs identified 3Target for potent first-strike influenza drugs identified 4Embryonic blood vessels that make blood stem cells can also make beating heart muscles 2Embryonic blood vessels that make blood stem cells can also make beating heart muscles 3
Hamster serum...
... Cy5 Post-Labeling Reactive Dye Pack, ... CyDye fluors specifically optimized for microarray ... 40000 pmol reactive dye per vial, ... to use, individually dispensed, and packed ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
Biology Products: